About Flap endonuclease 1
Flap endonuclease 1 (FEN1) is a protein
from Homo sapiens identified by UniProt accession
P39748, 380 residues long.
MolForge cross-references it against 0 known binders and
458 disease associations.
Target properties
| Protein name | Flap endonuclease 1 |
|---|
| UniProt accession | P39748 |
|---|
| Gene | FEN1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 380 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (458)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.50
- HIV infection · score 0.37
- lysophosphatidylethanolamine measurement · score 0.27
- breast adenocarcinoma · score 0.25
- endometrial cancer · score 0.22
- hepatocellular carcinoma · score 0.21
- oral squamous cell carcinoma · score 0.21
- phosphatidylcholine measurement · score 0.21
- esophageal squamous cell carcinoma · score 0.20
- clear cell renal carcinoma · score 0.19
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P39748-F1 | alphafold | PREDICTED | 89.63 | — |
Amino-acid sequence (380 residues)
MGIQGLAKLI ADVAPSAIRE NDIKSYFGRK VAIDASMSIY QFLIAVRQGG DVLQNEEGET TSHLMGMFYR TIRMMENGIK PVYVFDGKPP QLKSGELAKR SERRAEAEKQ LQQAQAAGAE QEVEKFTKRL VKVTKQHNDE CKHLLSLMGI PYLDAPSEAE ASCAALVKAG KVYAAATEDM DCLTFGSPVL MRHLTASEAK KLPIQEFHLS RILQELGLNQ EQFVDLCILL GSDYCESIRG IGPKRAVDLI QKHKSIEEIV RRLDPNKYPV PENWLHKEAH QLFLEPEVLD PESVELKWSE PNEEELIKFM CGEKQFSEER IRSGVKRLSK SRQGSTQGRL DDFFKVTGSL SSAKRKEPEP KGSTKKKAKT GAAGKFKRGK
Explore Flap endonuclease 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets